Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma

類似資料

• Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
  著者:: Lou, Emil, 等
  出版事項: (2013)
• The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide and Irinotecan for Newly Diagnosed Glioblastoma
  著者:: Vredenburgh, James J., 等
  出版事項: (2011)
• Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
  著者:: Affronti, Mary Lou, 等
  出版事項: (2018)
• Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma
  著者:: Ghiaseddin, Ashley, 等
  出版事項: (2017)
• A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab
  著者:: Affronti, Mary Lou, 等
  出版事項: (2016)